Baker Brothers Life Sciences LP, Director, 10% Owner at Neoleukin Therapeutics, Inc. (NLTX), bought 4,470,209 shares at $0.69 ($2.9M) on 2023-08-17, disclosed to the SEC on 2023-08-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.63 | 143,519 | $90K | 3.2% |
| 2 | $0.63 | 143,519 | $90K | 3.2% |
| 3 | $0.63 | 1,740,581 | $1.1M | 38.4% |
| 4 | $0.63 | 1,740,581 | $1.1M | 38.4% |
| 5 | $0.67 | 4,342 | $3K | 0.1% |
| 6 | $0.67 | 358 |
| $240 |
| 0.0% |
| 7 | $0.68 | 17,124 | $12K | 0.4% |
| 8 | $0.68 | 366 | $249 | 0.0% |
| 9 | $0.68 | 4,434 | $3K | 0.1% |
| 10 | $0.68 | 207,676 | $141K | 4.9% |
| 11 | $0.68 | 207,676 | $141K | 4.9% |
| 12 | $0.69 | 5,041 | $3K | 0.1% |
| 13 | $0.69 | 7,676 | $5K | 0.2% |
| 14 | $0.69 | 61,134 | $42K | 1.5% |
| 15 | $0.69 | 93,091 | $64K | 2.3% |
| 16 | $0.69 | 93,091 | $64K | 2.3% |
| Total | $0.64 avg | 4,470,209 | $2.9M | 100% |
| Filing → |
| IGMS | BUY | 2023-12-15 | $5.4M | — | Filing → |
| MDGL | BUY | 2023-11-21 | $22.1M | — | Filing → |
| BGNE | SELL | 2023-11-14 | $198.6M | — | Filing → |